Vancouver tPA study thought first of its kind

Kent, Heather
October 1998
CMAJ: Canadian Medical Association Journal;10/06/98, Vol. 159 Issue 7, p751
Academic Journal
Focuses on a Vancouver, British Columbia study to see if tissue plasminogen activator (tPA) will improve the survival rate of patients in a state of pulseless electrical activity following cardiac arrest. Reason that this study is unique; Details of how the study will be conducted; Ethical issues concerning patient consent.


Related Articles

  • Could experimental drug stop strokes? Gray, Valerie Lynn // Black Enterprise;May97, Vol. 27 Issue 10, p132 

    Presents information on experimental drug tissue plasminogen activator (TPA) which help stop stroke in progress. Its route of administration; Stroke prevention; Comparison of Blacks with White patients with stroke.

  • Tissue Plasminogen Activator in Cardiac Arrest with Pulseless Electrical Activity. Abu-Laban, Riyad B.; Christenson, James M.; Innes, Grant D.; van Beek, Catherina A.; Wanger, Karen P.; McKnight, R. Douglas; MacPhail, Iain A.; Puskaric, Joe; Sadowski, Richard P.; Singer, Joel; Schechter, Martin T.; Wood, Victor M. // New England Journal of Medicine;5/16/2002, Vol. 346 Issue 20, p1522 

    Background: Coronary thrombosis and pulmonary thromboembolism are common causes of cardiac arrest. We assessed whether the administration of tissue plasminogen activator (t-PA) during cardiopulmonary resuscitation would benefit patients with cardiac arrest and pulseless electrical activity of...

  • Stopping a `brain-attack'.  // Consumer Reports on Health;Feb97, Vol. 9 Issue 2, p19 

    Reports on the approval of the clot-dissolving drug TPA which stands for tissue plasminogen activator (brand name, Activase) for the treatment of thrombotic stroke. Symptoms; Article published in `The Lancet,' June 29, 1996.

  • DVT Prophylaxis: First Comparison of Catheter- Directed Thrombolysis versus Standard Care. Canavan, Neil // American Health & Drug Benefits;Feb Special Issue 2012, Vol. 5, p23 

    The article reports on the results of the Catheter-Directed Venous Thrombolysis study, which found that treating a blood clot with the drug alteplase reduced the frequency of postthrombotic syndrome and improved the medical outcomes of patients with proximal deep-vein thrombosis.

  • Platelet to lymphocyte ratio: a novel and simple predictor of slow coronary flow. Gündüz, Sabahattin; Yesin, Mahmut; Kalçık, Macit; Gürsoy, Mustafa Ozan; Özkan, Mehmet; Tanyeli, Ömer // Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi;Aug2015, Vol. 15 Issue 8, p679 

    A letter to the editor in response to the research "Stuck aortic valve treated by reteplase in a Bentall patient" by Ömer Tanyeli and others that was published in a 2015 issue, along with response from the author, are presented.

  • Stroke thrombolysis in Mombasa--an outreach service. Cohen, David // Practical Neurology (BMJ Publishing Group);Dec2011, Vol. 11 Issue 6, p372 

    The article presents a case study of a 73-year-old man who had a period of lightheadedness and was hypotensive and developed dysarthria. It says that the patient had undergone computed tomography (CT) brain scan wherein no hemorrhage was detected. It says that he was referred to a thrombolysis...

  • T-PA OK'd for ischemic stroke; 3 hours after onset is crucial time.  // Geriatrics;Aug96, Vol. 51 Issue 8, p23 

    Reports on the approval of the use of recombinant tissue plasminogen activator (t-PA) as an emergency treatment for ischemic stroke. Reduction of risk of disability; Need for early treatment; Risks.

  • Acute stroke therapy: Perspectives on current, future treatments. Lutsep, Helmi L.; Clark, Wayne M. // Formulary;Oct97, Vol. 32 Issue 10, p1040 

    Focuses on tissue plasminogen activator (t-PA) as an acute stroke therapy. Information on tissue plasminogen activator in stroke; Investigation on thrombolytics and neuroprotective agents.

  • Fibrin clots dissolve quickly after injection. Henahan, John F. // Ophthalmology Times;10/2/95, Vol. 20 Issue 38, p1 

    Reports on ophthalmologist Burhard Dick's use of low dose recombinant tissue plasminogen activator (rt-PA) to dissolve severe fibrin clots after cataract surgery. Absence of toxic intraocular side effects; Case history if Dick's patients; Evaluation of the potential for low dose rt-PA for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics